| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.23 | 0.2 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.094 | 0.2 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |